BAR­DA, Emer­gent BioSo­lu­tions break off $600M Covid-19 vac­cine man­u­fac­tur­ing deal

Af­ter a fi­as­co sur­round­ing the con­t­a­m­i­na­tion of Covid-19 vac­cine dos­es in its fa­cil­i­ties — dur­ing a time in which vac­ci­nat­ing res­i­dents was dire to Amer­i­ca’s re­turn …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER